237 related articles for article (PubMed ID: 31101710)
21. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
Burnouf T; Terpstra F; Habib G; Seddik S
Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
[TBL] [Abstract][Full Text] [Related]
22. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
23. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins.
Brorson K; Krejci S; Lee K; Hamilton E; Stein K; Xu Y
Biotechnol Bioeng; 2003 May; 82(3):321-9. PubMed ID: 12599259
[TBL] [Abstract][Full Text] [Related]
24. Proceedings of the 2009 Viral Clearance Symposium.
Miesegaes G; Bailey M; Willkommen H; Chen Q; Roush D; Blümel J; Brorson K
Dev Biol (Basel); 2010; 133():3-101. PubMed ID: 21516942
[TBL] [Abstract][Full Text] [Related]
25. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
26. Characterization of operating parameters for XMuLV inactivation by low pH treatment.
Chinniah S; Hinckley P; Connell-Crowley L
Biotechnol Prog; 2016; 32(1):89-97. PubMed ID: 26488618
[TBL] [Abstract][Full Text] [Related]
27. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
28. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
29. Viral validation design of a manufacturing process.
Larzul D
Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
[TBL] [Abstract][Full Text] [Related]
30. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
31. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
32. Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes.
Panjwani S; Cui I; Spetsieris K; Mleczko M; Wang W; Zou JX; Anwaruzzaman M; Liu S; Canales R; Hesse O
Biotechnol Prog; 2021 May; 37(3):e3135. PubMed ID: 33527773
[TBL] [Abstract][Full Text] [Related]
33. Proceedings of the 2019 Viral Clearance Symposium, Session 8. Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments and Actions.
Bolton G
PDA J Pharm Sci Technol; 2022; 76(4):362-367. PubMed ID: 34911826
[TBL] [Abstract][Full Text] [Related]
34. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
35. Validation of biopharmaceutical purification processes for virus clearance evaluation.
Darling A
Mol Biotechnol; 2002 May; 21(1):57-83. PubMed ID: 11989660
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.
Torgeman A; Mador N; Dorozko M; Lifshitz A; Eschar N; White MD; Wolf DG; Epstein E
Biologicals; 2017 Jul; 48():24-27. PubMed ID: 28633975
[TBL] [Abstract][Full Text] [Related]
37. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
38. Viral clearance capability of monoclonal antibody purification.
Cai K; Anderson J; Utiger E; Ferreira G
Biologicals; 2024 Feb; 85():101751. PubMed ID: 38387156
[TBL] [Abstract][Full Text] [Related]
39. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
40. Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies.
Schwantes A; Specht R; Chen Q
PDA J Pharm Sci Technol; 2018; 72(5):498-510. PubMed ID: 30030357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
